Specialty Products - Overview
Glenmark has earned a reputation as a leading, research-led global Indian pharmaceutical company with a strong focus on developing branded and generics products in dermatology, respiratory and oncology among other therapy areas. Over the past decades, Glenmark has made significant efforts to move up the value chain by developing specialty medicines and high-end innovation in addition to complex generics.
In 2020, Glenmark Pharma launched its first global branded specialty medicine, RYALTRIS®, an intranasal spray for the treatment of seasonal allergic rhinitis. RYALTRIS® is a unique combination of two molecule, which works by reducing the effect of histamine, and inhibiting inflammation in the nasal passage. The product was approved by the U.S. Food and Drug Administration (FDA) in 2022 and has since been launched in multiple markets across the globe.
RYALTRIS® (olopatadine hydrochloride and mometasone furoate monohydrate), an anti-allergy nasal spray, is being marketed globally for a treatment option for seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
Another product in line with its research-led efforts is Remo®. Glenmark was the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 diabetes in India under two brand names Remo MV and Remozen MV.
Glenmark was also the first company to launch FabiFlu® and oral drug Favipiravir (FabiFlu®) in India for the treatment of mild to moderate COVID-19 cases which has helped in the treatment of more than 5 million patients till date.